Intellia Therapeutics

📖 Wiki Page

company708 wordssynced 2026-04-02

Intellia Therapeutics

Intellia Therapeutics (NASDAQ: NTLA) is a clinical-stage biotechnology company leading the development of CRISPR/Cas9 technologies for gene editing and gene therapy. Founded in 2014 as a spinout from Novartis, Intellia is headquartered in Cambridge, Massachusetts.

Overview

flowchart TD companies_intellia["Intellia Therapeutics"] style companies_intellia fill:#4fc3f7,stroke:#333,color:#000 companies_intellia_0["Technology Platform"] companies_intellia -->|"includes"| companies_intellia_0 style companies_intellia_0 fill:#81c784,stroke:#333,color:#000 companies_intellia_1["CRISPR/Cas9 with LNP Delivery"] companies_intellia -->|"includes"| companies_intellia_1 style companies_intellia_1 fill:#ef5350,stroke:#333,color:#000 companies_intellia_2["Platform Capabilities"] companies_intellia -->|"includes"| companies_intellia_2 style companies_intellia_2 fill:#ffd54f,stroke:#333,color:#000 companies_intellia_3["Pipeline"] companies_intellia -->|"includes"| companies_intellia_3 style companies_intellia_3 fill:#ce93d8,stroke:#333,color:#000 companies_intellia_4["Clinical Programs"] companies_intellia -->|"includes"| companies_intellia_4 style companies_intellia_4 fill:#4fc3f7,stroke:#333,color:#000 companies_intellia_5["Neurological Disease Programs"] companies_intellia -->|"includes"| companies_intellia_5 style companies_intellia_5 fill:#81c784,stroke:#333,color:#000

...

Intellia Therapeutics

Overview

Mermaid diagram (expand to render)

| Attribute | Details | [@ntla2001]
|-----------|---------| [@regeneron2023]
| Founded | 2014 | [@pipeline2024]
| Headquarters | Cambridge, Massachusetts, USA | [@vivo2020]
| IPO | NASDAQ: NTLA (2018) |
| Market Cap | ~$4B (2024) |
| Employees | ~600 |
| Website | intelliatx.com |

Technology Platform

CRISPR/Cas9 with LNP Delivery

Intellia specializes in lipid nanoparticle (LNP) delivery for in vivo gene editing:

Cas9: Proprietary Cas9 formulations
Guide RNA: Synthetic single guide RNAs
Delivery: Proprietary LNPs for tissue-specific targeting
Advantages: Non-viral, repeatable dosing

Platform Capabilities

In vivo gene knockout: Precisely silence disease-causing genes

In vivo gene insertion: Insert therapeutic genes

Base editing: Single-nucleotide modifications

Prime editing: All types of edits including insertions/deletions

Pipeline

Clinical Programs

| Program | Indication | Target | Status |
|---------|------------|--------|--------|
| NTLA-2001 | Transthyretin (ATTR) amyloidosis | TTR | Phase 3 |
| NTLA-2002 | Hereditary angioedema | KLKB1 | Phase 1/2 |
| NTLA-3001 | Alpha-1 antitrypsin deficiency | SERPINA1 | Phase 1 (IND cleared) |

Neurological Disease Programs

Amyotrophic Lateral Sclerosis (ALS)

Target: SOD1 gene mutations
Approach: Knockout of mutant SOD1
Status: Discovery
Partner: Regeneron

Alzheimer's Disease

Target: Amyloid-related genes
Approach: Gene silencing
Status: Discovery

Parkinson's Disease

Target: GBA1 and other risk genes
Approach: Correct or modulate expression
Status: Discovery

Autonomic Dysfunction and GBA1 in Parkinson's Disease

Intellia's Parkinson's disease program targeting [GBA1](/genes/gba1) is particularly relevant for autonomic dysfunction:

GBA1 and Autonomic Symptoms

Heterozygous GBA1 mutations are the most common genetic risk factor for PD and are associated with:

Earlier Onset: GBA-PD patients develop symptoms ~5 years earlier
More Severe Autonomic Dysfunction: Higher prevalence of orthostatic hypotension, constipation, and urinary dysfunction
Faster Progression: More rapid decline in both motor and non-motor symptoms

Gene Therapy Approach

Intellia's CRISPR-based approach offers potential benefits:

Gene Correction: Potentially restore glucocerebrosidase activity, improving lysosomal function
Autonomic Neuron Protection: Protect the [dorsal motor nucleus of the vagus](/cell-types/dorsal-motor-nucleus-vagus) and [enteric neurons](/cell-types/enteric-neurons-pd) from alpha-synuclein pathology
Disease Modification: Address the root cause rather than just symptoms

Relevant Mechanisms

| Target | Autonomic Relevance |
|--------|---------------------|
| GBA1 | Lysosomal dysfunction, alpha-synuclein accumulation |
| Additional risk genes | May be identified for autonomic-specific targeting |

Clinical Progress

| Year | Milestone |
|------|-----------|
| 2014 | Founded as Novartis spinout |
| 2018 | IPO on NASDAQ |
| 2020 | First in vivo CRISPR data in humans (NTLA-2001) |
| 2021 | Positive Phase 1 data for NTLA-2001 |
| 2023 | Regeneron partnership ($400M upfront) |
| 2024 | Phase 3 enrollment for NTLA-2001 |

Key Partnerships

Regeneron Pharmaceuticals

Focus: Neurological diseases, CNS delivery
Programs: ALS, Alzheimer's, others
Deal Value: $400M upfront, $2B+ in milestones

Novartis

Focus: Original LNP technology license
Programs: Various in vivo programs

Competitive Landscape

| Company | Technology | Key Differentiator |
|---------|------------|---------------------|
| CRISPR Therapeutics | Ex vivo editing | First FDA-approved CRISPR therapy |
| Editas Medicine | In vivo CRISPR | CRISPR/Cas12a |
| Beam Therapeutics | Base editing | Precision editing |
| Intellia | LNP delivery | In vivo systemic delivery |

NTLA-2001: First Systemic CRISPR

NTLA-2001 is the first systemically delivered CRISPR gene-editing therapy to show clinical activity:

Target: TTR protein (transthyretin)
Results: Up to 89% reduction in TTR protein
Dosing: Single intravenous infusion
Durability: Sustained reduction for 12+ months

NeuroWiki Cross-References

CRISPR Gene Editing
[Gene Therapy](/therapeutics/gene-therapy-neurodegeneration) Lipid Nanoparticles
Companies Index
[RNAi Therapeutics](/genes/th)
[CRISPR-Cas9](/proteins/spr)
[Gene Therapy](/therapeutics/gene-therapy)
[Alzheimer's Disease Pipeline Companies](/companies/ad-pipeline-companies)
[Parkinson's Disease Pipeline Companies](/companies/pd-neurogenesis-companies)
[GBA1 Gene](/genes/gba1)
[Autonomic Dysfunction in Parkinson's Disease](/diseases/autonomic-dysfunction-in-corticobasal-syndrome)
[Enteric Neurons](/cell-types/enteric-neurons-pd)
[Dorsal Motor Nucleus of the Vagus](/cell-types/dorsal-motor-nucleus-vagus)

External Links

[Intellia Therapeutics Website](https://intelliatx.com)
[Intellia Therapeutics Pipeline](https://intelliatx.com/pipeline/)

References

Unknown, Intellia Therapeutics Official Website (n.d.)

[Unknown, NTLA-2001 Clinical Data (2021) (2001)](https://doi.org/10.1056/NEJMoa2107454)

Unknown, Regeneron Partnership (2023) (2023)

Unknown, Pipeline Overview (2024) (2024)

[Unknown, In Vivo CRISPR Delivery (2020) (2020)](https://doi.org/10.1126/science.abo4003)

📖 View canonical wiki page →